CN105611933B - 抗增生性化合物 - Google Patents

抗增生性化合物 Download PDF

Info

Publication number
CN105611933B
CN105611933B CN201480055129.0A CN201480055129A CN105611933B CN 105611933 B CN105611933 B CN 105611933B CN 201480055129 A CN201480055129 A CN 201480055129A CN 105611933 B CN105611933 B CN 105611933B
Authority
CN
China
Prior art keywords
alkyl
carbocyclyl
alkenyl
groups
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480055129.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105611933A (zh
Inventor
B·K·阿尔布雷克特
S·F·拜隆
V·S·格林
J-C·阿尔芒热
Y·勒布朗
J·梁
S·R·马格努森
V·H-W·崔
B·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Constellation Pharmaceuticals Inc
Original Assignee
Genentech Inc
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Constellation Pharmaceuticals Inc filed Critical Genentech Inc
Publication of CN105611933A publication Critical patent/CN105611933A/zh
Application granted granted Critical
Publication of CN105611933B publication Critical patent/CN105611933B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201480055129.0A 2013-09-05 2014-09-04 抗增生性化合物 Active CN105611933B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361874310P 2013-09-05 2013-09-05
US61/874,310 2013-09-05
PCT/US2014/054114 WO2015035062A1 (en) 2013-09-05 2014-09-04 Antiproliferative compounds

Publications (2)

Publication Number Publication Date
CN105611933A CN105611933A (zh) 2016-05-25
CN105611933B true CN105611933B (zh) 2019-01-25

Family

ID=51541384

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480055129.0A Active CN105611933B (zh) 2013-09-05 2014-09-04 抗增生性化合物

Country Status (9)

Country Link
US (1) US9505767B2 (https=)
EP (1) EP3041474B1 (https=)
JP (1) JP6336598B2 (https=)
KR (1) KR20160049003A (https=)
CN (1) CN105611933B (https=)
CA (1) CA2922925A1 (https=)
MX (1) MX2016002794A (https=)
RU (1) RU2016112568A (https=)
WO (1) WO2015035062A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2903968T3 (en) 2012-10-02 2017-01-30 Gilead Sciences Inc INHIBITORS OF HISTON DEMETHYLASES
PE20151667A1 (es) 2013-02-27 2015-11-27 Epitherapeutics Aps Inhibidores de histona desmetilasas
KR20150130491A (ko) * 2013-03-13 2015-11-23 제넨테크, 인크. 피라졸로 화합물 및 그것의 용도
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
RU2684396C2 (ru) 2014-10-29 2019-04-09 Донг-А Ст Ко., Лтд. Новые соединения пиридопиримидинона для модулирования каталитической активности гистонлизиндеметилаз (KDMS)
EP3294313A4 (en) * 2015-05-15 2019-04-17 The General Hospital Corporation METHODS RELATING TO THE PREVENTION AND TREATMENT OF DRUG RESISTANCE
JP6832430B2 (ja) 2016-08-31 2021-02-24 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞代謝過程の阻害剤
EP3525786A4 (en) * 2016-10-12 2020-03-18 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
EP3525785B1 (en) * 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
US11124795B2 (en) 2017-02-28 2021-09-21 University Of Massachusetts Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia
CN108947985A (zh) * 2017-05-22 2018-12-07 苏州偶领生物医药有限公司 用作自噬调节剂的化合物及其制备方法和用途
JP2020531519A (ja) 2017-08-21 2020-11-05 ナビゲン，インコーポレーテッド Ａｒｆ６阻害剤及び関連する方法
SG11202002218VA (en) * 2017-09-15 2020-04-29 Aduro Biotech Inc Pyrazolopyrimidinone compounds and uses thereof
AU2020307544A1 (en) * 2019-06-24 2021-11-18 Dana-Farber Cancer Institute, Inc. E3 ligase binders and uses thereof
EP3999183A4 (en) * 2019-07-17 2023-11-15 Ono Pharmaceutical Co., Ltd. COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES
CN114728167B (zh) 2019-11-25 2024-03-19 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
WO2023134692A1 (zh) * 2022-01-13 2023-07-20 浙江同源康医药股份有限公司 多环类化合物及其用途
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
WO2025194015A1 (en) * 2024-03-15 2025-09-18 Dem Biopharma, Inc. Heteroaryl modulators of gpr84 and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0531901A2 (en) * 1991-09-09 1993-03-17 Fujisawa Pharmaceutical Co., Ltd. Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity
EP1238979A1 (en) * 1999-12-13 2002-09-11 Eisai Co., Ltd. Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same
US20070072881A1 (en) * 2002-09-04 2007-03-29 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20120088775A1 (en) * 2009-06-08 2012-04-12 Peking University Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1996003397A1 (en) 1994-07-21 1996-02-08 Akzo Nobel N.V. Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998050038A1 (en) 1997-05-06 1998-11-12 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
BR9814116A (pt) 1997-11-06 2000-10-03 American Cyanamid Co Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
JP4100865B2 (ja) * 1999-12-13 2008-06-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 三環式縮合異項環化合物、その製造法およびその医薬
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
EP2069351B1 (en) * 2006-06-20 2015-10-28 AbbVie Inc. Pyrazoloquinazolinones as parp inhibitors
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
US10953012B2 (en) 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
US10392389B2 (en) 2012-10-25 2019-08-27 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
ES2635016T3 (es) * 2013-03-01 2017-10-02 Fundación Para La Investigación Médica Aplicada Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas
KR20150130491A (ko) 2013-03-13 2015-11-23 제넨테크, 인크. 피라졸로 화합물 및 그것의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0531901A2 (en) * 1991-09-09 1993-03-17 Fujisawa Pharmaceutical Co., Ltd. Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity
EP1238979A1 (en) * 1999-12-13 2002-09-11 Eisai Co., Ltd. Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same
US20070072881A1 (en) * 2002-09-04 2007-03-29 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20120088775A1 (en) * 2009-06-08 2012-04-12 Peking University Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators;Jinlong Qi等;《European Journal of Medicinal Chemistry》;20110122;第46卷(第3期);934-943 *
Indazolylpyrazolopyrimidine as Highly Potent B-Raf Inhibitors with in Vivo Activity;Xiaolun Wang等;《J. Med. Chem》;20101020;第53卷(第21期);7874-7878 *
Parallel Liquid-Phase Synthesis of 5-(1H-4-Pyrazolyl)-[1,2,4]oxadiazole Libraries;BORISOV 等;《JOURNAL OF COMBINATORIAL CHEMISTRY》;20090827;第11卷(第6期);1023-1029 *
Synthesis and Benzodiazepine Receptor Affinity of Pyrazolo[1,5-a]pyrimidine Derivatives. 3. New 6-(3-Thienyl) Series as r1 Selective Ligands;Silvia Selleri等;《J. Med. Chem》;20030101;第46卷(第2期);310-313 *
Synthesis and biological activities of some new fully fused quinazoline derivatives;IBRAHIM S.S.等;《INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY》;19980131;第37B卷(第1期);62-67 *
Synthesis, benzodiazepine receptor affinity and in vivo testing of 3-aryl-4,7-dihydro-6-(Nr-alkylpyrazol-3"- or 5"-yl)pyrazolo[1,5-a]pyrimidin-7-ones;S Selleri等;《Eur J Med Chem》;19970101;第1997年卷(第32期);941-953 *

Also Published As

Publication number Publication date
WO2015035062A1 (en) 2015-03-12
KR20160049003A (ko) 2016-05-04
JP2016529312A (ja) 2016-09-23
HK1221421A1 (zh) 2017-06-02
US9505767B2 (en) 2016-11-29
EP3041474A1 (en) 2016-07-13
EP3041474B1 (en) 2020-03-18
JP6336598B2 (ja) 2018-06-06
CN105611933A (zh) 2016-05-25
CA2922925A1 (en) 2015-03-12
US20150065522A1 (en) 2015-03-05
RU2016112568A3 (https=) 2018-08-08
MX2016002794A (es) 2016-09-13
RU2016112568A (ru) 2017-10-06

Similar Documents

Publication Publication Date Title
CN105611933B (zh) 抗增生性化合物
JP6847844B2 (ja) 治療用ピリダジン化合物およびその使用
JP7014765B2 (ja) ピラゾロ化合物及びその使用
CN107912040B (zh) 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
JP6669744B2 (ja) ブロモドメインのインヒビターとしての置換ピロロピリジン
JP6286472B2 (ja) プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
JP6639497B2 (ja) ブロモドメインインヒビターおよびその使用
CN107074824B (zh) 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物
CN107108614A (zh) 作为布罗莫结构域抑制剂的取代的吡咯并吡啶
EP2742040A1 (en) Indazole compounds, compositions and methods of use
CN107406418B (zh) 4,5-二氢咪唑衍生物及其作为组蛋白脱甲基酶(kdm2b)抑制剂的用途
HK40079390A (en) Substituted pyrrolopyrdines as inhibitors of bromodomain
HK1221421B (zh) 抗增生性化合物
HK40091510A (zh) 作为布罗莫结构域抑制剂的经取代的吡咯并吡啶
HK1242695B (zh) 作為用於治療癌症的pcaf和gcn5抑制劑的式(i)的酞嗪衍生物
HK1248696B (zh) 治療性噠嗪化合物及其用途
HK1243076B (zh) 作為布羅莫結構域抑制劑的取代的吡咯並吡啶
HK1247194B (zh) 4，5-二氫咪唑衍生物及其作為組蛋白脫甲基酶(kdm2b)抑制劑的用途
HK1243072B (zh) 布羅莫結構域抑制劑及其用途
HK1226056B (zh) 吡唑並化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1221421

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant